What does the half-life of Immunoglobulin G (IgG) mean?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 5, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Understanding the Half-Life of IgG

The half-life of IgG refers to the time it takes for the concentration of Immunoglobulin G in the bloodstream to decrease by 50%, which is approximately 3-4 weeks (21-30 days) for most IgG subclasses. 1, 2

Clinical Significance of IgG Half-Life

  • The half-life of IgG is a critical factor in determining the duration of protection provided by passive immunization with immunoglobulin preparations 1
  • Protection from passive immunization typically lasts for at least one half-life of IgG, which is approximately 3 weeks according to the Centers for Disease Control and Prevention 3
  • The half-life affects dosing intervals in patients receiving immunoglobulin replacement therapy for primary immunodeficiency diseases 4

IgG Half-Life by Subclass

  • IgG1: approximately 29.7 days 2
  • IgG2: approximately 26.9 days 2
  • IgG3: approximately 15.7 days (notably shorter than other subclasses) 2
  • Total IgG: approximately 25.8 days 2

More recent studies have found similar but slightly longer half-lives:

  • Total IgG: median of 36.1 days (range 18.5-65.9 days) 4
  • IgG subclasses: 26.7-38.0 days 4

Clinical Applications

Passive Immunization Scheduling

  • The recommended intervals between administration of antibody-containing products and measles- or varicella-containing vaccines are based on the estimated half-life of 30 days for passively acquired antibody 3
  • These intervals are extrapolated from the observed interference with immune response to measles vaccine for 5 months after a dose of 80 mg IgG/kg 3

Immunoglobulin Replacement Therapy

  • For patients receiving intravenous immunoglobulin (IVIG) therapy, dosing intervals of 3-4 weeks are common, aligning with the half-life of IgG 4
  • Trough IgG levels remain relatively constant when IVIG is administered at these intervals 4
  • Specific antibodies within IVIG preparations (such as those against cytomegalovirus, tetanus toxoid, and various pathogens) generally have half-lives similar to total IgG 4, 5

Factors Affecting IgG Half-Life

  • Individual variation: Half-lives can be highly variable between patients, ranging from 22 to 96 days in some studies 6
  • Serum IgG concentration: Some evidence suggests that patients with higher serum IgG concentrations may have different clearance rates 6
  • Disease state: Patients with certain conditions may have altered IgG metabolism 2

Clinical Pitfalls and Considerations

  • The half-life of IgG3 is significantly shorter than other subclasses, which may affect protection against certain pathogens where IgG3 is the predominant antibody 2, 5
  • When calculating protection periods after passive immunization, clinicians should consider that protection generally lasts for at least one half-life of IgG (approximately 3 weeks) 3, 1
  • Dosing intervals for IVIG therapy should account for the half-life to maintain adequate trough levels between infusions 4
  • The half-life of specific antibodies within immunoglobulin preparations generally follows that of total IgG, ensuring continued protection against targeted pathogens throughout the dosing interval 5

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.